Articles tagged with: Physician Column

News, Opinion»

[ by | Apr 24, 2014 8:27 am | 9 Comments ]
The Myeloma Quiz - April 2014

The Beacon is pleased to introduce our newest myeloma thought leader col­um­nist, Dr. Ravi Vij. Every three months, Dr. Vij will share with us a new edition of “The Myeloma Quiz,” which will test your knowledge and under­standing of the myeloma-related research published during the pre­vi­ous several months.

We hope you will join us in welcoming Dr. Vij to the Beacon community, and in thank­ing him for sharing with us his valuable perspectives.

The relentless grind in the battle against myeloma continues. The last several months have seen some …

Read the full story »

News, Opinion»

[ by | Jan 25, 2014 9:58 am | 14 Comments ]
Top 10 Discoveries Of 2013 In Multiple Myeloma

Last year, 2013, was a great year for myeloma research.

We had a number of important discoveries that will impact diagnosis, moni­tor­ing, prognosis, and treatment of the disease. Some new findings provide us with a better understanding of myeloma biology and mecha­nisms of drug resistance, while others present information that immedi­ate­ly impacts how patients are man­aged.

Collectively, these discoveries represent a significant advance to­wards our goal of curing myeloma.

I present here my list of the top 10 most compelling scientific findings and discoveries of 2013 in the field of …

Read the full story »

News, Opinion»

[ by | Aug 10, 2013 10:08 am | 22 Comments ]
Should Myeloma Patients Panic If They Do Not Achieve A Complete Response?

Over the last year or two, I have seen an increasing number of patients with multiple myeloma who are deeply worried that they have “failed” treatment because they are not in “complete response” (CR).  This phe­nom­e­non is gaining further steam with recent interest in “minimal re­sid­ual disease” (MRD).

In fact, with numerous educational programs, daily emails, and ubiqui­tous lectures touting a new regimen with even higher complete re­sponse rates, I am now almost as worried as them. Of course, the cause of my worry is not that patients have not …

Read the full story »

News, Opinion»

[ by | Apr 23, 2013 1:47 pm | 6 Comments ]
Beyond Kyprolis And Pomalyst: What Is Next On The Horizon?

Within the past nine months, two new agents have been approved for the treat­ment of relapsed multiple myeloma.

In July 2012, a second generation proteasome inhibitor, Kyprolis (car­filzomib), was approved for patients with relapsed/refractory disease. In February of this year, Pomalyst (pomalidomide) was approved for use in similar patients.

These two agents, with dexamethasone (Decadron) or in combination with other drugs, should further broaden the armamentarium for the treatment of myeloma as we continue to strive to make myeloma a chronic disease.

Rather than …

Read the full story »

News, Opinion»

[ by | Jul 13, 2012 11:43 am | 15 Comments ]
To Maintain Or Not To Maintain – That Is The Question!

Currently, there are three major controversies in multiple myeloma patient management: early versus late transplant, treat or observe ‘high-risk’ smoldering myeloma, and whether to use maintenance therapy. The latter is predominantly an issue following autologous stem cell transplantation.

In May, one of the world’s premier medical journals, the New England Journal of Medicine, published three articles about clinical trials comparing Revlimid (lenalidomide) maintenance versus observation.  In two of the studies, Revlimid maintenance was given following autologous stem cell transplantation.  In the third study, Revlimid maintenance was given following conventional …

Read the full story »